Elevation Oncology (NASDAQ:ELEV) Earns Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV) in a research note published on Friday morning, Benzinga reports. Wedbush currently has a $8.00 target price on the stock.

A number of other equities research analysts have also issued reports on the stock. JMP Securities reissued a market outperform rating and issued a $7.00 price target on shares of Elevation Oncology in a report on Thursday, March 7th. HC Wainwright reiterated a buy rating and set a $6.00 target price on shares of Elevation Oncology in a report on Tuesday, April 9th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of Buy and a consensus price target of $7.25.

Elevation Oncology Trading Down 3.1 %

NASDAQ ELEV opened at $3.70 on Friday. Elevation Oncology has a 1-year low of $0.36 and a 1-year high of $5.89. The stock has a 50-day moving average of $4.38 and a 200-day moving average of $2.42. The company has a debt-to-equity ratio of 0.41, a current ratio of 46.22 and a quick ratio of 46.22.

Elevation Oncology (NASDAQ:ELEV) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02. Research analysts expect that Elevation Oncology will post -0.87 earnings per share for the current fiscal year.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.